Janux Therapeutics, Inc. is a pharmaceutical company based in the United States, focused on developing innovative therapeutics for cancer patients. With an ESG score of 28.8, the company has a medium risk profile. Janux Therapeutics is utilizing its proprietary tumor-activated T Cell Engager platform technology to create next-generation treatments.